The High Court has overturned a primary care trust's refusal to fund cancer drug Revlimid for a cancer suffer with only months to live.
West Sussex PCT ruled that Revlimid would not be cost-effective and that 55-year-old Colin Ross's case was no exception. The drug is funded by some other trusts in England and Scotland.
The judge said the exceptions policy operated by West Sussex PCT was unlawful and said Mr Ross should receive Revlimid as an exceptional case.
Mr Ross will now receive the treatment at the Royal Marsden Hospital in London. The PCT is considering whether to appeal the ruling.